Business · 14/12/2010Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for SAMSCA Patent Extension
Summary
The FDA has published a notice determining the regulatory review period for SAMSCA, a human drug product, in response to patent extension applications submitted to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Health and Human ServicesOpen original release →